Posts by: Iqra Mumal, MSc

Iqra Mumal, MSc

Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.

March 19, 2020March 23, 2020

Urine Biomarkers Can Be Used to Develop Test for Prostate Cancer, Study Finds

News

Patients with prostate cancer exhibit changes in the levels of some urinary molecules compared with people with benign prostate diseases and healthy individuals, a study found, suggesting that these changes ... Read more

February 20, 2020February 20, 2020

Adding Provenge to Xtandi, Zytiga Reduces Risk of Death by 45% in mCRPC Patients, Data Shows

News

Adding the immunotherapy Provenge (sipuleucel-T) to a regimen containing the oral agents Zytiga (abiraterone acetate) or Xtandi (enzalutamide) significantly extends the lives of men with metastatic castration-resistant prostate cancer (mCRPC) in ... Read more

December 4, 2019

High Blood Levels of 2 Hormones May Be Linked to Prostate Cancer Development, Study Says

News

High blood levels of two hormones — insulin-like growth factor-I (IGF-I) and free testosterone — are associated with increased risk of prostate cancer later in life, a new study suggests. The study, ... Read more

September 26, 2019

Eating Mushrooms May Prevent Prostate Cancer, Japanese Study Suggests

News

Eating mushrooms frequently — three times a week or more — may have a reduced risk of prostate cancer compared to those eating mushrooms less than once a week, a ... Read more

June 17, 2019June 17, 2019

Most Prostate Cancer Patients on Active Surveillance Don’t Follow Monitoring Guidelines, Study Shows

News

Most prostate cancer patients who choose to undergo active surveillance instead of treatment are not receiving the appropriate disease monitoring, bringing into question whether or not this is a safe ... Read more

May 13, 2019

Evidence Supports Stereotactic Body Radiotherapy as a Standard of Care for Localized PC

News

Cumulative evidence to date supports the implementation of stereotactic body radiotherapy — a highly precise radiation therapy delivered in shorter periods of time — as a standard treatment for people ... Read more

April 15, 2019April 15, 2019

Prostate Cancer’s Risk and Mortality Rates Dropping or Stabilizing in Most Countries, 5-Year Data Shows

News

Prostate cancer’s incidence and deadliness has declined or stabilized in much of the world in recent years, with the greatest decrease in risk evident in the U.S., a study reports. ... Read more

August 6, 2018

Long-term Use of Cholesterol-lowering Medications May Benefit Some Prostate Cancer Patients, Trial Shows

News

Long-term treatment with atorvastatin, a cholesterol-lowering medicine, may reduce the proliferation of prostate cancer cells in some patients, a randomized trial suggests. Results from the trial were published in the study, ... Read more

August 2, 2018

Study Uncovers How Genetic Mutation Causes Aggressive Forms of Prostate Cancer

News

A type of mutation in a single nucleotide called rs11672691 plays a role in the development of aggressive prostate cancer by increasing the levels of two genes, PCAT19 and CEACAM21, a study ... Read more

July 26, 2018

Long-term ADT Use Can Diminish Tumors’ Visibility on Scans, Study Reports

News

Long-term use of androgen deprivation therapy (ADT) can make prostate cancer lesions difficult or impossible to see on some imaging scans, even in tumors that continue to grow, a new study shows. ... Read more